News briefing: CG Oncology nets $47M Series D for bladder cancer studies; Single-cell transcriptomic startup raises $24M launch cash
CG Oncology has some new cash to play with.
The Irvine, CA-based biotech announced Thursday it closed a $47 million Series D round of preferred stock financing as the company continues to advance late-stage trials for its lead program, CG0070. With the money, CG expects to fund an ongoing Phase III study in non-muscle invasive bladder cancer as a monotherapy, as well as a combo Phase II trial with Merck’s Keytruda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.